Drugs & Targets Elsevier to integrate NCCN guidelines into Via Oncology November 09, 2018Vol.44 No.42
Drugs & TargetsFree FDA approves Keytruda + carboplatin and either paclitaxel or nab-paclitaxel for first-line metastatic squamous NSCLC November 02, 2018Vol.44 No.41
Drugs & TargetsFree FDA accepts sNDA for Lonsurf for metastatic gastric/gastroesophageal junction adenocarcinoma; grants Priority Review November 02, 2018Vol.44 No.41
Drugs & TargetsFree Venclexta + Gazyva reduced risk of disease worsening or death in previously untreated CLL with co-morbidities November 02, 2018Vol.44 No.41
Drugs & TargetsFree TESARO achieves Zejula prostate cancer development milestone by Janssen November 02, 2018Vol.44 No.41
Drugs & TargetsFree Cofactor Genomics launches ImmunoPrism kit for use in clinical sequencing laboratories November 02, 2018Vol.44 No.41
Drugs & Targets FDA accepts sNDA for Lonsurf for metastatic gastric/gastroesophageal junction adenocarcinoma; grants Priority Review October 26, 2018Vol.44 No.40
Drugs & Targets BMS provides update on regulatory review of Opdivo + Yervoy in first-line lung cancer October 26, 2018Vol.44 No.40
Drugs & Targets Zai Lab announces approval of Zejula in relapsed ovarian cancer in Hong Kong October 26, 2018Vol.44 No.40
Drugs & Targets NCCN awarded $2M to study Taiho’s Trifluridine and Tipiracil in various cancers October 26, 2018Vol.44 No.40
